Application of DECR1 as target spot in breast cancer
Through DECR1 as a target, screening and treatment methods for breast cancer were developed, and the problem of insufficient breast cancer treatment targets in the prior art was solved. Knocking down the DECR1 expression level reduced the proliferation and invasion ability of breast cancer cells, and improved the Treatment effect.
Patent Information
- Application Number
- CN202410179090.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-08
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art has limited targets in breast cancer treatment, especially in patients with advanced breast cancer, and the research on strategies to target tumor iron death is not profound enough, resulting in limited clinical application.
Using DECR1 as a target to develop screening, treatment and prognosis kits for breast cancer, and to improve the sensitivity of anti-tumor drugs by knocking down DECR1 expression levels, evaluate the role of DECR1 in breast cancer progression, revealing its regulation The key mechanism of iron death.
High DECR1 expression level is related to poor breast cancer prognosis. Knocking down DECR1 expression can reduce the proliferation, migration and invasion of breast cancer cells, increase the probability of ferrous death in cells, and provide a new breast cancer treatment strategy.
Smart Images

Figure CN119082297A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to the application of DECR1 as a target in breast cancer. Background Art
[0002] Breast cancer is the most common tumor in women, and the incidence and mortality rates have remained high. Although breast cancer has been widely studied, the treatment options for patients with advanced breast cancer are limited and the treatment effect is poor. Therefore, it is of great clinical significance and scientific research value to find new and effective breast cancer treatment targets and develop potential anti-tumor drug candidates.
[0003] Metabolic reprogramming is considered to be one of the hallmarks of tumors, including glycolysis, oxidative phosphorylation, amino acid metabolism, and fatty acid metabolism. Generally, rapidly proliferating tumor cells require a large amount of fatty acids to synthesize phospholipids to promote cell membrane formation. In addition, fatty acids can also serve as raw materials for mitochondrial ATP production and play a role in regulating protein function. Therefore, fatty acids play an important role in the occurrence and development of tumors, and interfering with the fatty acid metabolism of tumor cells may become an effective strategy for tumor treatment.
[0004] Cell membranes and organelle membranes are rich in polyunsaturated fatty acids. However, excessive ROS generated by polyunsaturated fatty acid reactions can lead to cell damage and accumulation of lipid peroxides, resulting in ferroptosis of cells. Ferroptosis plays a vital role in various diseases, such as tumors, osteoporosis, and cardiovascular diseases. It is well known that lipid peroxidation induced by cellular oxidative stress is the basis for ferroptosis. Although tumor cells are more susceptible to oxidative stress, tumor cells can usually produce NADPH, GSH and other reductants to reduce cellular ROS levels and maintain cellular redox homeostasis, thereby avoiding ferroptosis. Strategies targeting tumor ferroptosis have shown exciting results, but their clinical application is still subject to many limitations due to the lack of clarity and depth of related research. Summary of the invention
[0005] In view of the above-mentioned deficiencies of the prior art, the present invention aims to provide the application of DECR1 as a target in breast cancer, and proposes to use DECR1 as a target in the screening, treatment and prognosis of breast cancer, so as to provide a new idea for the treatment of breast cancer.
[0006] In order to solve the above problems, the present invention adopts the following technical solutions:
[0007] Application of a reagent for detecting DECR1 expression level in preparing a breast cancer and / or breast cancer prognosis screening kit.
[0008] A use of DECR1 as a target in screening and / or preparing drugs for preventing and / or treating breast cancer.
[0009] An application of DECR1 as a target in screening drugs that improve the sensitivity of anti-tumor drugs in the prevention and / or treatment of breast cancer.
[0010] A breast cancer marker, which is the DECR1 expression level in breast cancer tissue.
[0011] As an implementable method, the DECR1 expression level in breast cancer tissue is higher than that in normal tissue; the degree to which the DECR1 expression level in breast cancer tissue is higher than that in normal tissue is positively correlated with the poor prognosis of breast cancer; the high expression of DECR1 is correlated with the poor prognosis of breast cancer.
[0012] As an implementable method, the expression level of DECR1 in breast cancer is positively correlated with the proliferation, migration and invasion ability of breast cancer cell lines; knocking down the expression level of DECR1 in breast cancer reduces the proliferation, migration and invasion ability of breast cancer cell lines.
[0013] As an implementation method, the expression level of DECR1 in breast cancer is correlated with mitochondrial ROS and Fe 2+ The level of DECR1 in breast cancer was negatively correlated with the content of MDA; knocking down the expression level of DECR1 in breast cancer cells reduced the mitochondrial ROS and Fe 2+ The level and MDA content increased.
[0014] As an implementable method, the expression level of DECR1 in breast cancer tissue is negatively correlated with the probability of ferroptosis of breast cancer cells; knocking down the expression level of DECR1 in breast cancer increases the probability of ferroptosis of breast cancer tissue cells.
[0015] As a feasible implementation method, the expression level of DECR1 in breast cancer is positively correlated with the PC content in breast cancer cells; the expression level of DECR1 in breast cancer is negatively correlated with the AA content in breast cancer cells; the expression level of DECR1 in breast cancer is negatively correlated with the PLA2G12A expression level in breast cancer cells; knocking down the expression level of DECR1 in breast cancer reduces the PC content in breast cancer cells; knocking down the expression level of DECR1 in breast cancer increases the AA content in breast cancer cells; knocking down the expression level of DECR1 in breast cancer increases the PLA2G12A expression level in breast cancer cells.
[0016] As a feasible implementation method, the PLA2G12A expression level in breast cancer cells is negatively correlated with the PC content in breast cancer cells, and positively correlated with the AA content in breast cancer cells; the PLA2G12A expression level in breast cancer cells is positively correlated with the probability of ferroptosis of breast cancer cells.
[0017] The beneficial effects of the present invention are: the present invention evaluates the specific role of DECR1 in the progression of breast cancer, identifies it as a therapeutic target for breast cancer, reveals that the regulatory effect on ferroptosis is the key mechanism of action of DECR1 in promoting the progression of breast cancer, and provides new therapeutic strategies and ideas for the treatment of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 This is the expression of fatty acid metabolism related genes in breast cancer tissues and normal tissues in the TCGA-BRCA-1096 dataset in Example 2 of the present invention.
[0019] Figure 2 A is the Kaplan-Meier curve diagram of patients with DECR1 expression above and below the critical value (calculated by the "bestssurv" algorithm) in Example 2 of the present invention; B is the relationship between DECR1 expression and survival probability estimated by data in the TCGA-BRCA-1096 data set (n=788); C is the relationship between DECR1 expression and survival probability estimated by data in the GEO96058 data set.
[0020] Figure 3 Representative images of IHC staining of DECR1 in breast cancer tissues (n=140) and normal breast tissues (n=77) in Example 2 of the present invention.
[0021] Figure 4 This is a diagram showing the protein expression of DECR1 in breast cancer tissue and normal breast tissue based on the IHC staining results in Example 2 of the present invention.
[0022] Figure 5 This is a Kaplan-Meier curve diagram of OS of patients whose DECR1 expression is higher and lower than the critical value according to the IHC staining results in Example 2 of the present invention.
[0023] Figure 6 This is a probability diagram of the Nomogram predicting the OS of cancer patients in Example 2 of the present invention; related factors include age, site, pathological T stage (T), pathological N stage (N), American Joint Committee on Cancer (AJCC) stage and DECR1 expression listed on the dot axis. The 5-year and 10-year OS probabilities are plotted to calculate the OS incidence *P<0.05, **P<0.01.
[0024] Figure 7 This is a proliferation diagram of MDA-MB-231 cells after knocking down DECR1 in Example 2 of the present invention.
[0025] Figure 8 This is a proliferation diagram of BT474 cells after knocking down DECR1 in Example 2 of the present invention.
[0026] Fig. 9 This is a diagram of cell migration after DECR1 knockdown in breast cancer cells (MDA-MB-231 and BT474) observed in the scratch assay in Example 2 of the present invention.
[0027] Fig.10 This is a diagram of invasion assay using a Transwell chamber with a Matrigel-coated membrane after knocking down DECR1 in MDA-MB-231 and BT474 cells in Example 2 of the present invention.
[0028] Fig.11 This is a graph showing the number of invaded cells after knocking down DECR1 in MDA-MB-231 and BT474 cells using a Transwell chamber with a Matrigel-coated membrane in Example 2 of the present invention.
[0029] Fig.12 This is a diagram showing the effect of knocking down DECR1 on the tumorigenicity of breast cancer cells in a subcutaneous xenograft model established in NOD-SCID mice in Example 2 of the present invention; tumors derived from MDA-MB-231 and BT474 (NC, shDECR1-1, shDECR1-2) cells were isolated (n=5 in each group).
[0030] Fig.13 The growth graph of the tumor derived from MDA-MB-231 cells in Example 2 of the present invention was drawn every two days after the tumor volume reached approximately 50 mm3; *P<0.05, **P<0.01.
[0031] Fig.14 The growth graph of the tumor derived from BT474 cells in Example 2 of the present invention was drawn every two days after the tumor volume reached approximately 50 mm3; *P<0.05, **P<0.01.
[0032] Fig.15 This is a diagram of the mitochondrial morphology observed using TEM after DECR1 knockout in Example 2 of the present invention.
[0033] Fig.16 This is a diagram of quantifying mitochondrial ROS levels using MitoSOX staining in MDA-MB-231 cells with stable knockdown of DECR1 in Example 2 of the present invention; the fluorescence intensity was quantified using flow cytometry, and the mitochondrial ROS level was expressed as the mean fluorescence intensity value.
[0034] Fig.17 In Example 2 of the present invention, MitoSOX staining was used to quantify mitochondrial ROS levels in BT474 cells with stable knockdown of DECR1; flow cytometry was used to quantify fluorescence intensity, and mitochondrial ROS levels were expressed as mean fluorescence intensity values.
[0035] Fig.18 The intracellular Fe in MDA-MB-231 cells after knocking down DECR1 using the FerroOrange assay kit in Example 2 of the present invention is 2+ Horizontal flow cytometry analysis.
[0036] Fig.19 The intracellular Fe in BT474 cells after knocking down DECR1 using the FerroOrange assay kit in Example 2 of the present invention is 2+ Horizontal flow cytometry analysis.
[0037] Fig. 20 This is a graph showing the measurement of MDA content in MDA-MB-231 cells with stable knockdown of DECR1 in Example 2 of the present invention, *P<0.05, **P<0.01.
[0038] Fig.21 This is a graph showing the measurement of MDA content in BT474 cells with stable knockdown of DECR1 in Example 2 of the present invention, *P<0.05, **P<0.01.
[0039] Fig. 22 This is a volcano plot of non-targeted metabolomics to identify dysregulated metabolites in DECR1 knockdown compared with negative control MDA-MB-231 and BT474 cells in Example 2 of the present invention.
[0040] Fig.23 This is an expression diagram of the metabolism-related gene PLA2G12A after knocking down DECR1 in Example 2 of the present invention.
[0041] Fig.24 This is a graph showing the PLA2G12A content after knocking down DECR1 in breast cancer cells in Example 2 of the present invention.
[0042] Fig.25 This is a graph showing the contents of seven PCs in MDA-MB-231 cells with stably knocked-down DECR1 determined by mass spectrometry in Example 2 of the present invention.
[0043] Fig.26 This is a graph showing the contents of seven PCs in BT474 cells with stably knocked-down DECR1 determined by mass spectrometry in Example 2 of the present invention.
[0044] Fig. 27 This is a graph showing the intracellular AA content measured after knocking down DECR1 using ELISA in Example 2 of the present invention.
[0045] Fig.28This is a graph of AA content measured after further knocking out PLA2G12A using stable DECR1 knockout in breast cancer cells in Example 2 of the present invention.
[0046] Fig.29 This is a graph showing the quantification of mitochondrial ROS levels using MitoSOX staining in MDA-MB-231 cells with stable DECR1 knockout and further PLA2G12A knockout in Example 2 of the present invention; the fluorescence intensity was quantified using flow cytometry, and the mitochondrial ROS level was expressed as the mean fluorescence intensity value.
[0047] Fig.30 This is a graph showing the quantification of mitochondrial ROS levels using MitoSOX staining in BT474 cells with stable DECR1 knockout and further PLA2G12A knockout in Example 2 of the present invention; the fluorescence intensity was quantified using flow cytometry, and the mitochondrial ROS level was expressed as the mean fluorescence intensity value.
[0048] Fig.31 is the intracellular Fe after PLA2G12A knockdown in MDA-MB-231 cells with stable DECR1 knockdown in Example 2 of the present invention 2+ Horizontal flow cytometry analysis; *P<0.05, **P<0.01.
[0049] Fig.32 The intracellular Fe after PLA2G12A knockdown in BT474 cells with stable DECR1 knockdown in Example 2 of the present invention 2+ Horizontal flow cytometry analysis; *P<0.05, **P<0.01. DETAILED DESCRIPTION
[0050] The present invention is further described in detail below in conjunction with specific embodiments.
[0051] It should be noted that these embodiments are only used to illustrate the present invention rather than to limit the present invention. Simple improvements to the method based on the concept of the present invention all fall within the scope of protection claimed by the present invention.
[0052] Example 1 Methods and Materials
[0053] 1.1 Bioinformatics analysis
[0054] FAM-related genes were derived from the Kyoto Encyclopedia of Genes and Genomes (KEGG; https: / / www.genome.jp / kegg / ). Data from an independent cohort (TCGA-BRCA) containing 1096 cases were downloaded from The Cancer Genome Atlas (TCGA) and imported into R (version 4.1) (https: / / bioconductor.org / bioclite.r). In this cohort, 1045 cases were retained for further analysis because they had complete clinical follow-up data. A data set containing 3409 cases (GSE96058) was obtained from the GEO database, and the data of this data set were used to verify the gene expression and prognostic value of DECR1 in breast cancer patients. Survival analysis refers to normalizing the gene expression data and centering them with the mean, and drawing Kaplan-Meier curves to show the value of FAM-related genes in predicting the overall survival (OS) of patients. The outcome event was defined as “death”. The cutoff expression level of each gene was estimated using the best separation algorithm according to the R package “surfminer”. The log-rank test was used to analyze the data of the Kaplan-Meier plots and the results of the univariate Cox regression analysis. The correlation between DECR1 expression and OS rate was further evaluated by multivariate Cox regression analysis, and a nomogram was generated with the “rms” package based on the results of the multivariate Cox regression analysis.
[0055] Protein-protein interaction network: FAM-related genes were imported into the STRING database (https: / / cn.string-db.org / ) to obtain the protein-protein interaction network diagram. The degree, topological coefficient, and neighborhood connectivity of the genes were then scored using Cytoscape (version 3.7.0), and genes with all three scores higher than the median score were selected.
[0056] 1.2 Tissue microarray and immunohistochemical staining
[0057] A total of 140 breast cancer tissues and 77 paracancerous tissues were collected based on the completeness of clinical and pathological information and the availability of follow-up information. The diagnosis of these specimens was further verified by a pathologist. To construct the tissue microarray, a representative area was selected from the paraffin tissue of each sample. In addition, microarray sections were obtained by tissue microarray paraffin blocks. The Medical Ethics Committee of Shanghai Aoduo Biotechnology Co., Ltd. granted ethical approval for this project (approval number: SHYJC-CP-1901002; SHYJC-CP-1607006). The tissue microarray was incubated with rabbit monoclonal anti-DECR1 antibody (Abcam, ab198848) at a dilution of 1:100 at 4°C. The EnVision system was used for immunohistochemical staining. Diaminobenzidine (Dako, Glostrup, Denmark) was used for visualization of antibody binding. The staining intensity of DECR1 was calculated by Image ProPlus (version 6.0.0.260, USA).
[0058] 1.3 Cell culture
[0059] Cell culture: Human breast cancer cell lines MDA-MB-231 and BT474 were purchased from the American Type Culture Collection (ATCC). All cells were maintained in Dulbecco's modified Eagle medium (DMEM) or RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (Gibco, 10437028) and 1% penicillin / streptomycin (Gibco, 10378016) at 37°C in a humidified atmosphere of 5% CO2.
[0060] shDECR1 cell line construction.
[0061] 1.4 Cell function detection (cell viability, cell migration, cell invasion)
[0062] Cell viability: The cell counting kit-8 (CCK-8) cell proliferation assay kit (Solarbio, CA1210) was used to assess breast cancer cell viability. 5 The density of individual cells / mL is inoculated in 96-well plates and cultivated.After incubation for 48 hours with DMSO, 10 μL CCK-8 solution is added in culture medium, and cells are incubated for another 2 hours.OD is then measured at 450nm using a multi-well spectrophotometer (microplate reader).Cell viability is represented by the percentage of control (untreated) cell viability.
[0063] Cell migration: When MDA-MB-231 and BT474 cells were 100% confluent, a wound was made in the central area of each well using a 200 μL pipette tip. The wounded area was photographed at 0 and 24 h. Each experiment was repeated three times.
[0064] Cell invasion: Breast cancer cells were cultured in serum-free medium for 12 h. The cell concentration was adjusted to 4-5×10 5 Cells / mL. Transwell chamber (Corning, NY, USA) with Matrigel coating membrane is placed in 24-well plates. RPMI-1640 culture medium (500 μL) is placed in the bottom compartment, and 200 μL of cell suspension is placed in the upper compartment. Then, the cells are incubated for 24 hours. The cells on the lower surface of the membrane are fixed with glacial acetic acid for 15-30min, stained with crystal violet for 30 minutes, and counted. The experiment was repeated three times independently.
[0065] 1.5 Transmission electron microscopy
[0066] The morphological characteristics of breast cancer cells with ferroptosis were observed by transmission electron microscopy. The main steps are fixation: the sample was pre-fixed with 3% glutaraldehyde and then fixed with 1% osmium tetroxide; dehydration: acetone dehydration step by step, the concentration gradient of the dehydrating agent was 30%→50%→70%→80%→90%→95%→100% (100% concentration was changed 3 times); infiltration and embedding: the ratio of dehydrating agent and Epon812 embedding agent was 3:1, 1:1, 1:3, and finally Ep812 embedding. Ultrathin sections: Use an ultrathin slicer to prepare ultrathin sections of about 60 to 90 nm, spread the sections, and then scoop them onto a copper grid; Staining: First stain with uranyl acetate for 10 to 15 minutes, then stain with lead citrate for 1 to 2 minutes, and stain at room temperature; Electron microscopy observation: Use a JEM-1400FLASH transmission electron microscope produced by JEOL to capture images of the copper grid. Each copper grid is first observed at 6000 times, and the area to be observed is selected to capture images to observe the specific morphology of cells and organelles.
[0067] 1.6 Transcriptomic analysis
[0068] Transcriptome sequencing was performed using the previously constructed MDA-MB-231 and BT474 cell lines with stable knockdown of DECR1. First, 1×10 7 Each group of cells was replicated for 3 times, and then total RNA was extracted using the Trizol method. Then, the transcriptome sequencing library was constructed using the Illumina RNA library preparation kit (NEB, USA). Next, the library was sequenced on the Illumina NovaSeq platform. The raw reads in fastq format were processed. Then, the read counts of each gene were calculated by the featureCounts (version: 1.5.0) software package.
[0069] 1.7 Non-targeted metabolomics analysis
[0070] For non-targeted metabolomics, 1 × 10 7The cells were placed in EP tubes and the samples were resuspended in pre-cooled 80% methanol by vortexing. Then, the samples were thawed on ice and centrifuged for 30 seconds. After 6 minutes of ultrasonic treatment, the samples were centrifuged at 5000rpm, 4°C for 1 minute. The supernatant was freeze-dried and dissolved in 10% methanol. Finally, the solution was injected into the LC-MS / MS system for analysis. UHPLC-MS / MS analysis was performed using a Vanquish UHPLC system (ThermoFisher, Germany) coupled to an Orbitrap Q ExactiveTM HF mass spectrometer (ThermoFisher, Germany) of Novogene Co., Ltd. (Beijing, China). The raw data files generated by UHPLC-MS / MS were processed using Compound Discoverer 3.1 (CD3.1, ThermoFisher) to perform peak alignment, peak picking and quantification of each metabolite. The KEGG database, the Human Metabolome Database (HMDB; https: / / hmdb.ca / metabolites ), and the LIPIDMaps database ( http: / / www.lipidmaps.org / ) were used.
[0071] 1.8 Mass spectrometry analysis
[0072] The control or DECR1 knockdown MDA-MB-231 or BT474 cells were collected, and the cell number was about 1×10 7 Each group was repeated 5 times, and after collection, 70% methanol / water solution was added to grind and crush the cells. Then, the metabolites were extracted with chloroform solution. The metabolites containing chloroform were further concentrated in a concentration device. The concentrate was further dissolved in 300 μL of isopropanol: methanol (1:1) solution (containing 100 ng / mL internal standard PC (15:0 / 18:1-7)), centrifuged for 15 minutes, and the supernatant was retained for analysis. In addition, the PC (16:0-18:1) standard solution (500 ng / ml) was analyzed, and the internal standard concentration was 100 ng / ml. Chromatographic analysis was performed on Waters Acquity UPLC using an Acquity UPLC BEH amide column (1.7 μm, 2.1 mm×100 mm). The chromatographic separation conditions were: column temperature 45°C; flow rate, 0.300 mL / min. Metabolomic analysis was performed with mobile phase A (H2O: acetonitrile 5 mM; NH4AC, 95 / 5, v / v) and mobile phase B (H2O: methanol 5 mM; NH4AC 50 / 50, v / v, pH adjusted to 8.0 with aqueous ammonia) with the following elution gradient: 0–1 min, 0% B; 1–2 min, 50% B; 2–4 min, 100% B; 4–6 min, 0% B.
[0073] In addition, mass spectrometry analysis was performed on an AB SCIEX 5500 triple quadrupole (QQQ)-mass spectrometer using an electrospray ionization (ESI) source. Mass spectrometry was performed under the following conditions: curtain gas, 35 arb; collision gas, 9 arb; ion spray voltage, 4500 volts; temperature 450°C; ion source gas 1, 50 arb; and ion source gas 2, 50 arb. The final results were integrated using MultiQuant software, and the metabolite content was calculated using the internal standard method.
[0074] 1.9 Arachidonic acid content detection
[0075] MDA-MB-231 and BT474 cells were collected after DECR1 knockdown or treatment with Erigoster B (5 μM, 48 h). 6 150-200 μL PBS was added to each breast cancer cell for re-suspending. The cells were lysed by sonication and the supernatant was tested with an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. The arachidonic acid (AA) assay kit (E-EL-0051c) was purchased from Elabscence.
[0076] 1.10qRT-PCR
[0077] Total RNA was extracted and purified using TRIzol reagent (Magen, R4801-01). Next, reverse transcription was performed using a transcription kit (Vazyme, R122-01). Quantitative RT-PCR was performed using an ABI 7900 real-time PCR system. Finally, the data were analyzed using the 2-ΔΔCt method. The mRNA levels of the target genes were normalized to the levels of β-actin or GAPDH.
[0078] 1.11 Animal experiments
[0079] NOD-SCID mice were purchased from Hunan SJA Laboratory Animal Co., Ltd. The animals were housed in cages at 23 ± 2 °C and fed with standard laboratory diet and tap water throughout the experiment.
[0080] Orthotopic xenograft model: Mice were anesthetized with 4% chloral hydrate and 100 μL of 1x10 7 The cancer breast cell suspension of cells was injected into the mammary fat pad to establish an orthotopic xenograft model. For tumorigenesis assays, negative control (NC) MDA-MB-231 and BT474 cells, DECR1 knockdown (shDECR1) MDA-MB-231 and BT 474 cells, and 4T1 cells were injected. Tumors were measured every two days, and tumor volume was calculated as follows: Tumor volume = (length × width 2 ) / 2.
[0081] 1.12 Detection of ferroptosis-related indicators
[0082] To evaluate the ferroptosis of each group, MDA, ROS and Fe 2+ According to the instructions of the kit, a lipid peroxidation (MDA) assay kit (Beyotime Biotechnology, S0131S) was used.
[0083] 1.13 Computer-Assisted Virtual Screening
[0084] Receptors for virtual screening: Using the Protein Preparation Wizard Panel ( 2021) optimized the protein structure of DECR1 by correcting the bond order, adding hydrogen atoms, distributing charges, and predicting the protonation state (pH 7.0). Constrained energy optimization was performed using the OPLS4 force field to eliminate atomic conflicts in the structure, and the root mean square deviation (RMSD) of heavy atoms converged to And optimize the side chain position to obtain a reasonable side chain structure.
[0085] Preparation of compound libraries: Using the LigPrep panel ( 2021) were used to treat compounds from L6020. First, the compounds were protonated and desalted at pH 7.0 ± 2.0 using the Epik program to generate tautomers and maintain the original atomic chirality. To ensure the conformational diversity of small molecules during virtual screening, a maximum of 32 conformations were generated for each small molecule.
[0086] The screening was carried out in the following manner: Glide HTVS [High Throughput Virtual Screening mode] → GGlide SP [Standard Precision mode] → GGlide XP [Extra Precision]. The protein structure was set to rigid, the small molecule was set to flexible, and other parameters were set to default values. The docked structures were subjected to energy optimization, and the structures with docking scores within the top 50% were retained for the next round of screening. After removing duplicates and filtering for drug-like properties, visual inspection was performed. After the initial screening, approximately 15,000 small molecule compounds were obtained. After removing duplicate structures, 2,497 compounds were retained. QikProp was used to filter based on predicted absorption, distribution, metabolism, and excretion (ADME) properties (specified criteria: 0 < H-bond donors < 6, 150 < Mol Weight < 725). Compounds with a molecular weight greater than 725 and more than 6 H-bond donors were removed, resulting in a final set of 1,258 compounds. Then, Canvas was used to generate binary fingerprints for these 1,258 compounds, and hierarchical clustering was performed based on the Tanimoto similarity metric. Compounds with the highest docking score (in kcal / mol, where a lower value indicates a higher affinity between the receptor and ligand) were selected from each cluster. This process yielded a final set of 100 small molecule compounds representing different chemical structures.
[0087] 1.14 Surface Plasmon Resonance (SPR) Assay
[0088] The interaction between the analyte and the ligand was evaluated at room temperature using an OpenSPR instrument (Nicoya, Canada). First, according to the standard procedure, a COOH sensor chip was installed in the OpenSPR instrument. The buffer was run at maximum flow rate and degassing bubble parameters after reaching the signal baseline. Then, 10 mM glycine-HCl (pH 7.4) was injected onto the surface of the sensor chip. The chip was activated, and the prepared EDC and NHS solutions were injected to complete the functionalization of the chip surface. Then, the sample was injected at a flow rate of 20 μL / min.
[0089] Finally, different concentrations of the analyte were injected separately onto the surface of the ligand chip (specific concentrations are provided in the experimental results), and the analyte was sampled at a rate of 20 μL / min. The binding time of the analyte to the ligand was 240 s, and the natural dissociation time was 360 s. In each cycle, a 200 μL volume of the sample flowed through the chip at a constant flow rate of 20 μL / min for 240 s. The bound compounds were dissociated from the coated surface by treatment with acidic and basic solutions. After each measurement, treatment with 10 mM glycine-HCl (pH 1.5) was used to separate the small molecule and the target protein. Finally, the kinetic parameters of the binding reaction were calculated and analyzed using Trace Drawer software (Ridgeview Instruments AB, Sweden).
[0090] Example 2 Analysis Results
[0091] 2.1DECR1 is overexpressed in clinical breast cancer samples and is associated with poor prognosis in patients
[0092] See also Figure 1-6 , analyzed the expression of 84 fatty acid metabolism-related genes in breast cancer and adjacent tissues. First, 19 key genes were screened out by constructing a protein-protein interaction network based on Dgree and Neibo rankings. Then, the expression analysis of these 19 key genes showed that only DECR1 was expressed higher in breast cancer tissues than in adjacent tissues, and it was statistically significant. In addition, both TCGA and GEO96058 datasets showed that high expression of DECR1 was associated with poor prognosis of patients, so it was speculated that DECR1 has the potential to be a therapeutic target for breast cancer.
[0093] To further clarify the role of DECR1 in breast cancer, immunohistochemical staining analysis was performed on tissue microarrays constructed from 140 breast cancer clinical samples and 77 adjacent normal breast tissues. The results showed that compared with adjacent tissues, DECR1 was highly expressed in breast cancer tissues, and high expression of DECR1 was positively correlated with poor prognosis of patients.
[0094] 2.2 Effect of DECR1 on the malignant phenotype of tumor cells
[0095] Bioinformatics analysis was used to identify whether DECR1 has the potential to be a therapeutic target for breast cancer. A breast cancer cell line with stable knockdown of DECR1 was constructed by lentiviral transfection to clarify the effect of inhibiting DECR1 expression on the malignant phenotype of breast cancer cells. Figure 7-14 Compared with the control group, the proliferation, migration and invasion abilities of the DECR1 knockdown cell lines were inhibited. In addition, an orthotopic xenograft model of breast cancer was constructed by injecting breast cancer cells of different treatment groups into the mammary fat pad of NOD-SCID mice to determine the role of DECR1 in vivo. The results showed that after DECR1 expression was inhibited, the growth rate of tumor transplants decreased, and the tumor volume and size were significantly lower than those of the control group. In summary, these results suggest that DECR1 promotes the progression of breast cancer both in vivo and in vitro.
[0096] 2.3 Targeting DECR1 to induce ferroptosis in breast cancer cells
[0097] The protein encoded by DECR1 is an auxiliary enzyme for fatty acid β-oxidation. The degradation of PUFA requires the help of multiple auxiliary enzymes, including δ2, δ3-enoyl-CoA isomerase and NADPH-dependent 2,4-dienoyl-CoA reductase (DECR1). DECR1 can act as a negative regulator of androgen receptor in prostate cancer. Inhibition of DECR1 can lead to the accumulation of PUFA in cells, triggering cellular oxidative stress and lipid peroxidation, thereby inducing cell ferroptosis. PUFA-related lipid peroxidation is a characteristic and driving factor of ferroptosis. To explore whether the expression level of DECR1 in breast cancer cells will interfere with cell ferroptosis. See Figure 15-21 First, transmission electron microscopy was used to observe whether the morphological changes of cells after DECR1 knockdown were consistent with the characteristics of ferroptosis. Electron microscopy results showed that after DECR1 knockdown, the mitochondrial membrane density was concentrated, the number of mitochondrial cristae was reduced or absent, the mitochondrial outer membrane was ruptured, and the cell nucleus size was normal. The above characteristics are consistent with the characteristics of breast cancer cells undergoing ferroptosis. Therefore, inhibition of DECR1 expression will induce ferroptosis in breast cancer cells. In addition, mitochondrial ROS and Fe in DECR1 knockdown MDA-MB-231 and BT474 cells were detected. 2+ The levels of mitochondrial ROS and Fe in DECR1 knockdown MDA-MB-231 and BT474 cells were measured to indicate the level of ferroptosis. The mean fluorescence intensity showed that compared with the negative control cells, the levels of mitochondrial ROS and Fe in DECR1 knockdown MDA-MB-231 and BT474 cells were significantly higher than those in the negative control cells. 2+ The levels of DECR1 and DECR1 were significantly increased. In addition, the content of MDA, a product of cellular lipid oxidation, was detected, and it was found that the MDA content increased in breast cancer cells with stable knockdown of DECR1. These findings all indicate that DECR1 knockdown may induce ferroptosis of breast cancer cells.
[0098] 2.4 Targeting DECR1 induces ferroptosis in breast cancer cells by promoting phosphatidylcholine metabolism
[0099] To further explore the potential mechanism by which DECR1 promotes cancer progression by interfering with cellular ferroptosis, transcriptome sequencing was performed on DECR1-knockdown MDA-MB-231 and BT474 cells to identify genes that were dysregulated after DECR1 knockdown. Considering the key role of DECR1 in fatty acid oxidation and its profound impact on cellular metabolism, metabolomics analysis was also performed to identify metabolites with significant changes. Figure 22-32Through multi-omics combined analysis, it was found that after DECR1 knockdown, PC metabolism was activated, PC content decreased, and conversely, AA content increased. At the same time, increased PLA2G12A expression levels were observed in breast cancer cells with DECR1 knockdown. In addition, mass spectrometry was used to measure the content of various phospholipids in breast cancer cells with DECR1 knockdown. The results showed that inhibiting the expression of DECR1 significantly reduced the content of various PCs and increased the content of AA.
[0100] AA is an omega-6 PUFA with the widest distribution and important biological activities in the body. Under physiological conditions, AA is mainly bound to PC or phosphatidylethanolamine glycerol. Under certain stimuli, phospholipase A2 (PLA2) is activated and catalyzes the hydrolysis of phospholipid diacyl groups, resulting in the release of AA into cells in a free form. The AA metabolic pathway in the KEGG database showed that PC hydrolysis produced a large amount of AA under the catalysis of PLA2G12A. DECR1 knockdown cells showed an increase in PLA2G12A levels. In cells with stable knockdown of DECR1, further knockdown of PLA2G12A was accompanied by a decrease in intracellular AA content, and breast cancer cells were protected from ferroptosis. These results indicate that targeting the DECR1-PLA2G12A signaling axis in breast cancer can promote AA production by regulating phospholipid metabolism, activate cellular ferroptosis, and thus inhibit tumor progression.
[0101] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described with reference to the preferred embodiments of the present invention, it should be understood by those skilled in the art that various changes may be made in form and details without departing from the spirit and scope of the present invention as defined in the appended claims.
Claims
1. Use of a reagent for detecting DECR1 expression level in the preparation of a breast cancer and / or breast cancer prognosis screening kit.
2. An application of DECR1 as a target in screening and / or preparing drugs for preventing and / or treating breast cancer.
3. An application of DECR1 as a target in screening drugs that improve the sensitivity of anti-tumor drugs in the prevention and / or treatment of breast cancer.
4. A breast cancer marker, characterized in that: The breast cancer marker is the expression level of DECR1 in breast cancer tissue.
5. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: DECR1 is highly expressed in breast cancer tissues; the high expression of DECR1 is associated with a poor prognosis of breast cancer.
6. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: Knockdown of DECR1 expression level in breast cancer reduced the proliferation, migration and invasion abilities of breast cancer cell lines.
7. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: Knockdown of DECR1 expression in breast cancer reduces mitochondrial ROS and Fe 2+ The level and MDA content increased.
8. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: Knocking down the expression level of DECR1 in breast cancer increases the probability of ferroptosis of breast cancer cells.
9. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: Knocking down the expression level of DECR1 in breast cancer reduces the PC content in breast cancer cells; knocking down the expression level of DECR1 in breast cancer increases the AA content in breast cancer cells; knocking down the expression level of DECR1 in breast cancer increases the expression level of PLA2G12A in breast cancer cells.
10. The use according to any one of claims 1 to 3 or the breast cancer marker according to claim 4, characterized in that: The expression level of PLA2G12A in breast cancer cells is negatively correlated with the PC content in breast cancer cells, and positively correlated with the AA content in breast cancer cells; the expression level of PLA2G12A in breast cancer cells is positively correlated with the probability of ferroptosis of breast cancer cells.
